Colorado lawmakers are pushing forward with Senate Bill 26-066, a proposal that would tighten the rules around compounded GLP-1 weight-loss medications. The measure would force pharmacies and other sellers to verify where their active ingredients come from and spell out exactly what is in these custom-mixed shots. Backers describe it as a straight-up patient safety move, while critics worry it could effectively sideline some of the cheaper compounded options that have filled gaps during shortages.
Sen. Iman Jodeh, one of the bill’s sponsors, told Denver7 the aim is to make sure ingredients come from FDA-approved suppliers and that patients get clear information about what they are putting into their bodies. She emphasized that the bill is not designed to shut down compounding pharmacies and that it carves out room for doctors and hospitals that need to tailor treatments. Bariatric surgeon Dr. Katy Irani also told Denver7 that mass-produced GLP-1 medications are made under tight controls, while compounded versions can differ in fillers, dosing and purity.
What the bill would require
According to the bill text on the Colorado General Assembly site, pharmacies and sellers would have to confirm that compounded weight-loss medications are made from pharmaceutical-grade bulk drug substances and, when required, FDA-approved drugs, and that those ingredients were manufactured in line with FDA processes. Labels would need to list every active and inactive ingredient, the amount of each one, and its country of origin, along with a clear warning that the product is not FDA-approved. The proposal also calls for certificates of analysis, at least two years of recordkeeping, and a ban on false or misleading advertising of compounded GLP-1 products.
Enforcement and penalties
Local reporting says the state Board of Pharmacy could review records and levy fines of up to $1,000 per dose, while the attorney general would be able to enforce the measure as a deceptive trade practice under Colorado’s consumer-protection act. KOAA noted that sponsors plan to bring amendments on access and oversight when the bill hits committee hearings. Supporters argue that the bite in the penalty structure is meant to deter sketchy sourcing and mislabeled products, not to choke off legitimate medical compounding.
FDA warnings and the green list
The U.S. Food and Drug Administration has warned that some Americans are turning to unapproved compounded versions of semaglutide and tirzepatide and has created a "green list" import alert to help screen GLP-1 active pharmaceutical ingredients. The FDA says these unapproved compounds do not go through agency review for safety, effectiveness or quality, and it has issued warning letters to companies marketing certain compounded GLP-1 products. The agency has also received adverse-event reports and flagged dosing errors linked to some compounded formulations.
Access and cost concerns
Patients and consumer advocates told Denver7 that compounded GLP-1 medications have sometimes been a lower-cost option and easier to find during earlier shortages, and lawmakers say they tweaked parts of the bill after hearing those worries. The sponsors built in carve-outs to preserve clinicians’ ability to compound for patients with allergies or unusual dosing needs. Proponents say tighter rules on sourcing and labeling can protect patients while keeping medically necessary compounding in place.
What happens next
SB26-066 was introduced on January 28, and the Senate Health & Human Services Committee sent an amended version to the Committee of the Whole on March 5. The bill is still under debate, according to the Colorado General Assembly bill page. Colorado General Assembly records show sponsors expect further amendments and additional hearings as lawmakers keep working through the balance of safety, access and cost for the rest of the session. If enacted without a safety clause, standard timelines in Colorado would place the law’s effective date later in 2026.
